Oculus Innovative Sciences, Inc. Logo

Print Print page | Email Email page | PDF Download PDF | Add to Briefcase Add to briefcase
« Previous Release | Next Release »



Oculus Innovative Sciences to Present at OneMed Forum 2011 During JP Morgan Week in San Francisco

Presentation and Live Webcast on Wednesday, January 12, 2010 at 2:45 pm PST

PETALUMA, Calif.--(BUSINESS WIRE)-- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced that Hoji Alimi, the company's CEO and founder, will discuss the upcoming 2011 regulatory and commercial milestones during his presentation at the OneMed Forum 2011 to be held at the Sir Francis Drake Hotel in San Francisco, California. Mr. Alimi's presentation is scheduled on Wednesday, January 12 at 2:45 pm PST, with a breakout session to immediately follow.

To listen to the view the webcast, please visit www.ustream.tv/channel/onemedforum at least 15 minutes early to download any necessary software. Participation in the conference is by invitation only. For more information on the conference, please contact OneMed at www.onemedplace.com.

About Oculus Innovative Sciences

Oculus Innovative Sciences is a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing. The Microcyn Technology addresses the need for improved solutions in multiple markets including dermatology, oral care, cosmeceutical, wound care and others. It features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries under various country specific regulatory clearances and approvals. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores; increase blood flow to the wound site; and reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com.

Oculus Innovative Sciences, Microcyn, Dermacyn and Vetericyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

Oculus Innovative Sciences, Inc.
Dan McFadden, 425-753-2105
Director of Public and Investor Relations
dmcfadden@oculusis.com

Source: Oculus Innovative Sciences, Inc.

News Provided by Acquire Media

Close window | Back to top